Antihypertensive medications and their effects on lipid metabolism
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hypertension and hyperlipidemia are interrelated and share common pathophysiologic mechanisms, such as insulin resistance and endothelial dysfunction. Accumulating evidence shows that it is important to regulate hypertension and hyperlipidemia to reduce cardiovascular risk. However, medications such as β-blockers and thiazide diuretics, which are widely used for blood pressure regulation, are known to have several metabolic side effects. Despite deleterious effects on glucose metabolism and lipid metabolism, these medications have been proven to reduce cardiovascular risk. On the other hand, calcium channel blockers, angiotensin-converting enzyme inhibitors, and α-blockers have either no effect or favorable effects on the lipid profile. This review outlines the need to control hypertension, options for several antihypertensive medications, their differing effects on lipid metabolism, and the clinical implications of their effects on lipid parameters.
- National Center for Health Statistics: Health, United States, 2007 (with a chart book on the health of Americans). Available at http://CDC.gov/nchs/hus.htm. Accessed February 27, 2008.
- Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572. CrossRef
- Vasan RS, Larson MG, Leip EP, et al.: Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291–1297. CrossRef
- Perry HM Jr, Davis BR, Price TR, et al.: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000, 284:465–471. CrossRef
- Staessen JA, Thijs L, Fagard R, et al.: Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999, 282:539–546. CrossRef
- Almgren T, Persson B, Wilhelmsen L, et al.: Stroke and coronary heart disease in treated hypertension: a prospective cohort study over three decades. J Intern Med 2005, 257:496–502. CrossRef
- Andersson OK, Almgren T, Persson B, et al.: Survival in treated hypertension: follow up study after two decades. BMJ 1998, 317:167–171.
- Laakso M, Sarlund H, Mykkanen L: Insulin resistance with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990, 10:223–231.
- Lloyd-Jones DM, Evans JC, Larson MG, et al.: Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med 1999, 159:2206–2212. CrossRef
- MacMahon SW, Macdonald GJ, Blacket RB: Plasma lipoprotein levels in treated and untreated hypertensive men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study. Arteriosclerosis 1985, 5:391–396.
- Lepira FB, M’Buyamba-Kabangu JR, Kayembe KP, Nseka MN: Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension. Cardiovasc J S Afr 2005, 16:249–255.
- Lind L, Berne C, Lithell H: Prevalence of insulin resistance in essential hypertension. J Hypertens 1995, 17:1457–1462.
- Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607. CrossRef
- McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718. CrossRef
- Sakurai K, Sawamura T: Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 2003, 91:182–186. CrossRef
- Sawamura T: LOX-1, a lectin-like oxidized LDL receptor identified from endothelial cells, in endothelial dysfunction. Int Congr Ser 2004, 1262:531–534. CrossRef
- Dandapat A, Hu C, Sun L, Mehta JL: Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler Thromb Vasc Biol 2007, 27:2435–2442. CrossRef
- Norata GD, Grigore L, Raselli S, et al.: Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193:321–327. CrossRef
- Brook RD: Mechanism of different effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000, 2:370–377. CrossRef
- Kasiske BL, Ma JZ, Kalil RS, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122:133–141.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997. CrossRef
- Grimm RH, Flack JM, Grandits GA, et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996, 275:1549–1556. CrossRef
- McMahan CA, Gidding SS, Fayad ZA, et al.: Risk scores predict atherosclerotic lesions in young people. Arch Intern Med 2005, 165:883–890. CrossRef
- Appel GB, Radhakrishnan J, Avram MM, et al.: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003, 26:1402–1407. CrossRef
- Inoue T, Morooka T, Moroe K, et al.: Effect of telmisartan on cholesterol levels in patients with hypertension—Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007, 39:372–376. CrossRef
- Taylor EN, Hu FB, Curhan GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065–1070. CrossRef
- Ward KD, Sparrow D, Vokonas PS, et al.: The relationships of abdominal obesity, hyperinsulinemia and saturated fat intake to serum lipids levels: Normal Aging Study. Int J Obes Relat Metab Disord 1994, 18:137–144.
- Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374–381. CrossRef
- Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250–254.
- Bélanger M, Boulay P: Effect of an aerobic exercise training program on resting metabolic rate in chronically beta-adrenergic blocked hypertensive patients. J Cardiopulm Rehabil 2005, 25:354–360. CrossRef
- Jacob S, Henriksen EJ: Metabolic properties of vasodilating beta-blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2004, 6:690–696. CrossRef
- Remaley AT: Old drug, new tricks, the unexpected effect of doxazosin on high-density lipoprotein. Circ Res 2007, 101:116–118. CrossRef
- Lithell HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991, 14:203–209. CrossRef
- Khan N, McAlister FA: Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737–1742.
- Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Am J Cardiol 1985, 55:1–15.
- Antihypertensive medications and their effects on lipid metabolism
Current Diabetes Reports
Volume 8, Issue 3 , pp 214-220
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors